ProfileGDS5678 / 1423467_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 77% 76% 99% 83% 86% 82% 77% 87% 77% 68% 89% 71% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.045276
GSM967853U87-EV human glioblastoma xenograft - Control 25.2418977
GSM967854U87-EV human glioblastoma xenograft - Control 35.1222676
GSM967855U87-EV human glioblastoma xenograft - Control 411.207399
GSM967856U87-EV human glioblastoma xenograft - Control 56.0932183
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2370886
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8315582
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2070577
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7232387
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2256777
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1654568
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0548289
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4117671
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1751868